ArticleScientific reports2025
Impact of using oral spherical carbon adsorbent in predialysis chronic kidney disease period on cardiovascular outcome after dialysis therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiome remodeling in chronic kidney disease: implications of kidney replacement therapies and therapeutic interventions.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral spherical carbon adsorbent (OSCA), AST-120, has demonstrated efficacy in slowing the progression of chronic kidney disease (CKD). This study assessed the impact of OSCA administration during predialysis CKD period on cardiovascular outcomes after dialysis therapy. We conducted a retrospective cohort study with 294 patients, including 98 who received OSCA before dialysis (OSCA group) and 196 matched control by age and sex (control group). The primary outcome was cardiovascular events, and the secondary composite outcome included cardiovascular events and cardiovascular death post-dialysis initiation. The analysis of cardiovascular event-free survival revealed no difference between two groups (P = 0.228). However, when the OSCA group was further divided based on the duration of OSCA administration, the patients who received OSCA for ≥ 4 months presented significantly fewer cardiovascular events than those who received OSCA for shorter periods (P = 0.032). Multivariate Cox models revealed a reduced risk of cardiovascular events in the OSCA ≥ 4 months group compared to the control group (HR 0.39, 95% CI 0.18-0.84). Additionally, the OSCA ≥ 4 months group experienced significantly fewer composite outcome (HR 0.46, 95% CI 0.24-0.90). These findings indicate that longer-term OSCA use before dialysis initiation could reduce cardiovascular events and death post-dialysis, suggesting a potential 'legacy effect'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.